Page 2 - First Line Advanced News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from First line advanced. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In First Line Advanced Today - Breaking & Trending Today

Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Fi


Search jobs
10-Jan-2021
Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021

Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 –

2021 Net Product Revenue Guidance of $950 million to $1,050 million –
– Corporate priorities for 2021 include potentially filing supplemental New Drug Applications for cabozantinib in three additional indications –
– Presentation and webcast at 2021 J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 PM EST / 2:20 PM PST –
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full yea ....

United States , Chris Senner , Susan Hubbard , Bristol Myers Squibb , Michaelm Morrissey , Roche Ltd , Drug Administration , Bristol Myers Squibb Company , Public Affairs Investor Relations , Exchange Commission , Other Compounds Beginning Clinical Development , Exelixis Inc , Iconic Therapeutics Inc , Fourth Quarter , Full Year , Product Revenue Guidance , New Drug Applications , Healthcare Conference , Prescription Drug Use Fee Act , Exelixis Fourth Quarter , Chief Executive Officer , Investigational New Drug , First Line Advanced , Growing Commercial , Priority Review , Ipsen Pharma ,